BioHealth Innovation, Inc. (BHI), a regional private-public partnership focusing on commercializing market-relevant biohealth innovations and increasing access to early-stage funding in Central Maryland, announced today that Reg Seeto, M.D., has been appointed to the BHI Board of Directors. Dr. Seeto currently serves as Vice President, Head of Partnering & Strategy at MedImmune, the global biologics research and development arm of AstraZeneca.  

"It is a pleasure to welcome Reg to the BHI Board of Directors," said Doug Liu, Chair, BHI Board of Directors, and Senior Vice President of Global Operations for Qiagen. "Reg’s background in business development and partnering strategy will be an important asset to our Board as we give counsel to BHI in its fostering of startups in Central Maryland. We look forward to his contributions to this Board, to the BHI organization, and to the biohealth startup community."

Dr. Seeto rejoined the MedImmune Leadership Team in 2013 to lead the Partnering and Strategy Group after having spent a year as an executive abroad for AstraZeneca. He is responsible for MedImmune’s Business Development and Strategy teams, which deliver external partnership strategy for the organization. 

Partnership with Johns Hopkins and BioHealth Innovation, Inc. will speed 10 healthtech startups to market

Baltimore, MD and Philadelphia, PA — September 18th, 2013—DreamIt Ventures is pleased to announce the launch of DreamIt Health Baltimore, a partnership with The Johns Hopkins University and BioHealth Innovation, Inc. to recruit, invest in, and speed the growth and success of a select group of early-stage health IT companies. The program comes on the heels of a successful health IT program in Philadelphia also built on strong industry partnerships that give participants access and advantages typically out-of-reach to startups.

"The key to making health care more accessible is innovation, and the most fertile focus for health care innovation is in acquiring, storing, analyzing and sharing information," said Ronald J. Daniels, President of Johns Hopkins. "This accelerator project will have important implications for the future use of information as we use technology to find solutions for the most pressing health problems of our day. Just as important, it sets up Baltimore to become even more central to the health care information revolution through the rapid validation of solutions."

"Technology holds the potential to transform the way in which we approach health care in this country and around the world," said Paul Rothman, MD, Dean of the Johns Hopkins University School of Medicine and CEO of Johns Hopkins Medicine. "Johns Hopkins has been at the forefront in developing innovative solutions to the most pressing health care challenges. The partnership with DreamIt presents an exciting and unrivaled opportunity to develop the most cutting-edge solutions at the crossroads of information technology and medicine."

Richard Moore, BD DiagnosticsROCKVILLE AND BALTIMORE, MARYLAND, August 26, 2013 – BioHealth Innovation, Inc. (BHI), a regional private-public partnership focusing on commercializing market-relevant biohealth innovations and increasing access to early-stage funding in Central Maryland, announced today its selection of Richard Moore, M.D., Ph.D., as a new Entrepreneur-in-Residence (EIR) at the National Institutes of Health (NIH) Office of Technology Transfer (OTT). BHI and BD established this position in July 2013. Dr. Moore, an executive with decades of experience in diagnostics development and technology strategy, will help support the development of new start-up companies and product commercialization based upon innovative technologies selected via OTT license agreements.

BHI Also Announces Agreement With BD to Create Entrepreneur-in-Residence Position

BioHealth Innovation, Inc. (BHI) today announced the fiscal year 2013-2014 election of officers and a new appointment to its Board of Directors. BHI also announced it has entered into an agreement with BD (Becton, Dickinson and Company) to establish an entrepreneur-in-residence (EIR) position at the National Institutes of Health (NIH) Office of Technology Transfer. In conjunction with this agreement, BD is entitled to a voting position on the BHI Board of Directors, which will be held by Richard M. “Rick” Ivey, Worldwide Vice President Research & Development, BD Diagnostics - Diagnostic Systems.

"I am pleased to welcome the new roster of officers and a new member to the BHI Board of Directors," said Richard Bendis, BHI President and CEO. "The officers are a committed group of individuals who already have contributed to the steady growth of BHI, and will continue to be important leaders as the organization further develops."

"Rick Ivey joins the Board on behalf of BD as part of the terms of an agreement between BHI and BD to establish an NIH EIR position,” added Mr. Bendis. “He represents an important new addition to our Board as he is a seasoned medical technology executive who can offer experience and insights to the growing cadre of start-up diagnostics companies in the State of Maryland."

BioHealth Innovation, Inc. (BHI), a regional private-public partnership focusing on commercializing market-relevant biohealth innovations and increasing access to early-stage funding in Central Maryland, today announced its selection of Ram Aiyar, Ph.D., M.B.A., as the first Entrepreneur-in-Residence (EIR) for BHI at the National Institutes of Health’s (NIH) National Heart, Lung and Blood Institute (NHLBI). Dr. Aiyar will help advance fundamental research discoveries to new therapeutics, diagnostics and devices that can be used clinically and commercially.

“We’re pleased to add Dr. Aiyar to our roster of Entrepreneurs-in-Residence,” said Rich Bendis, BHI President and CEO. “He is now our third EIR – joining Todd Chappell, who is EIR at NIH, and Ken Malone, our EIR working with the University of Maryland Ventures. The growth of this program will be a benefit to BHI and our partner organizations for years to come, and will result in transitioning more early-stage biomedical technologies to commercial potential. ”

BioHealth Innovation, Inc. (BHI), a regional private-public partnership focusing on commercializing market-relevant biohealth innovations and increasing access to early-stage funding in Central Maryland, today announced its selection of Ken Malone, Ph.D., of Early Charm Ventures, as the first BHI Entrepreneur-in-Residence (EIR) assigned to work directly with UM Ventures. Dr. Malone, a serial entrepreneur who has founded or been an officer of five biotechnology or advanced materials companies, will help advance the commercialization efforts of new start-up companies based upon innovative discoveries coming out of research programs at the University of Maryland (UMD) College Park and Baltimore.

“We’re thrilled to name Ken Malone as an EIR,” said Richard Bendis, BHI President & CEO. “Ken and I have a long history of working together, so I know first hand that he has the experience, drive and perspective to be a true asset to BHI and to the many start-ups he’ll serve from University of Maryland in support of the newly launched UM Ventures initiative.” Dr. Malone will assist any interested UM start-ups once they have been launched.

- Technology Company Awarded Prize at Invest Maryland Challenge Ceremony -

BALTIMORE, MD, April 16, 2013 – University of Maryland (UM) Ventures, an ambitious joint research commercialization effort of the University of Maryland, Baltimore (UMB) and the University of Maryland, College Park (UMCP), announced today that it has awarded the first UM Ventures Start-Up Prize to VisiSonics, an Investment Maryland Challenge Semi Finalist company that was founded on intellectual property owned by the University. VisiSonics was recognized during the Invest Maryland Challenge Award Ceremony on Monday, April 15, 2013 at the Maryland Institute College of Art (MICA) in Baltimore, Maryland.

"Identifying customers and having sales is, of course, a major hurdle for university start-ups," said James L. Hughes, Director of UM Ventures, and President, Research Park Corporation, University of Maryland Baltimore. "With the significance of achieving more than half a million dollars in sales in 2012, VisiSonics is a worthy recipient of this inaugural prize."

- Multiple SBIR/STTR Submission Deadlines Quickly Approaching -

BioHealth Innovation, Inc. (BHI), a regional private-public partnership focusing on commercializing market-relevant biohealth innovations and increasing access to early-stage funding in Central Maryland, announced today the launch of its Commercial Relevance Program (CRP). BHI's CRP is designed to help life science companies navigate the complicated process of preparing applications for federal funding, inclusive of Small Business Innovation Research (SBIR), Small Business Technology Transfer (STTR), and other federal government awards.

"The federal grant application process can be very complex. Based on 2012 data released by the National Institutes of Health (NIH), Maryland ranks 32nd out of 50 states with regard to SBIR award success rates. We would like to improve on this – and are confident that the CRP will help companies be more successful with their submissions," said Ethan Byler, Director, Innovation Programs, BioHealth Innovation, Inc.

"At the end of the day, it's about helping Central Maryland companies to get the best results possible as they seek out federal grant awards as a means of non-dilutive funding," he added.

The CRP incorporates a pre-proposal review by knowledgeable BHI staff and advisors prior to a life science company's submission of a full proposal. Through this review process, applicants will receive a set of recommendations and tips for troubleshooting their proposal for federal funding.

Interested life science companies in Central Maryland should This email address is being protected from spambots. You need JavaScript enabled to view it. today for more information. The following federal agency SBIR/STTR deadlines are fast approaching:

• NIH SBIR/STTR Deadline - April 5, 2013
  http://grants.nih.gov/grants/funding/sbir.htm
• NSF SBIR/STTR Deadline - June 11, 2013
  http://www.nsf.gov/eng/iip/sbir/index.jsp
• DOD SBIR/STTR Deadline - June 26, 2013
  http://www.acq.osd.mil/osbp/sbir/sb/schedule.shtml

About BioHealth Innovation, Inc.
BioHealth Innovation, Inc., is a regional innovation intermediary focused on commercializing market-relevant bio-health innovations and increasing access to early-stage funding in Maryland. Learn more at www.biohealthinnovation.org.

ROCKVILLE, MARYLAND, March 4, 2013 – BioHealth Innovation, Inc. (BHI), a regional private-public partnership focusing on commercializing market-relevant biohealth innovations and increasing access to early-stage funding in Central Maryland, today announced that BioHealth Innovation, Inc. President & CEO Richard Bendis is scheduled to present at the upcoming SXSW 2013 conference and the 2013 BIO International Convention this Spring. Mr. Bendis is also serving on the Program Committee for AdvaMed 2013: The MedTech Conference, which will be held in Washington, DC, in September.

Specific information for each event is as follows:

• 2013 South By Southwest "SXSW" Conference, March 8-12, 2013, Austin Convention Center, Austin, Texas. Mr. Bendis is participating in a panel on Saturday, March 9, entitled, "Entrepreneurs-in-Residence: Not Just for VCs!" Venture capital firms have utilized the services of 'Entrepreneurs-in-Residence' (EIRs), seasoned innovators with functional expertise, to help spur entrepreneurship and fill gaps in expertise. This panel will look at the value of combining the 'innovation mojo' of EIRs with some of the government's brightest 'intrapreneurs' to solve the nation's most pressing challenges. Joining Mr. Bendis on the panel will be Arnaub Chatterjee (Associate Director of Health Information Partnerships, Merck - Office of the Chief Medical Information and Innovation Officer), John Paul Farmer (Senior Advisor to the U.S. CTO) and Zachery Jiwa, Health IT Advisor; Innovation Fellow, U.S. Department of Health and Human Services; Advisor, HIMSS State Advisory Roundtable.
  
  
• 2013 BIO International Convention, April 22-23, 2013, McCormick Place, Chicago, Illinois. Mr. Bendis is scheduled to be part of The Translational Research Forum on April 22, 2013, beginning at 1:30 p.m., and a panel discussion focused on effective strategies in developing accelerator models beginning at 4:35 p.m.
  
  
• AdvaMed 2013: The MedTech Conference, September 23-25, 2013, Walter E. Washington Convention Center, Washington, DC. Mr. Bendis is reviewing panel submissions in the eHealth IT Track.

ROCKVILLE, MARYLAND, February 11, 2013 – BioHealth Innovation, Inc. (BHI), a regional private-public partnership focusing on commercializing market-relevant biohealth innovations and increasing access to early-stage funding in Central Maryland, announced today the appointment of GenVec, Inc. President and Chief Executive Officer Cynthia L. Collins to its Board of Directors. BHI also announced that BHI Founding Board Member Jerry Parrott, formerly with Human Genome Sciences, has stepped down from his board seat but will continue to remain active on BHI's Commercial Relevance Advisory Board.

ROCKVILLE, MARYLAND, February 27, 2013 – BioHealth Innovation, Inc. (BHI), a regional private-public partnership focusing on commercializing market-relevant biohealth innovations and increasing access to early-stage funding in Central Maryland, announced today the formation of its Commercial Relevance Advisory Board (CRAB). Members of the CRAB represent diverse business and academic organizations from throughout the region, such as venture capital firm New Enterprise Associates, Ernst & Young, the Howard Hughes Medical Institute, the University of Maryland (UMD), Johns Hopkins University, and leading biotechnology companies.

BHI and Ahead are collaborating to accelerate commercialization of Symcat, Ahead Research’s patient/healthcare provider matchmaking app

ROCKVILLE, MARYLAND, Dec. 19, 2012 - BioHealth Innovation, Inc. (BHI) announced today that its newest client, Ahead Research, Inc. (Ahead), received the first Cigna Innovation Health Challenge award at the 2012 mHealth summit. BHI and Ahead recently signed a Memorandum of Understanding (MOU) to jointly accelerate the commercialization of Symcat, Ahead’s web and mobile application whose module was the basis for the Cigna award.

“Ahead Research – with its Symcat app – is the type of entrepreneurial start-up company that BioHealth Innovation seeks to foster as part of its mission to drive the commercialization of market-relevant biohealth innovations,” said BioHealth Innovation’s President & CEO Richard Bendis.

ROCKVILLE, MARYLAND, Dec. 19, 2012 - BioHealth Innovation, Inc. (BHI), a regional private-public partnership focusing on commercializing market-relevant biohealth innovations and increasing access to early-stage funding in Central Maryland, announced today the appointment of Emergent BioSolutions Inc. President and CEO Daniel J. Abdun-Nabi and SR One President Jens Eckstein, Ph.D., to the BHI Board of Directors.

"It is an honor to welcome two additional life science industry leaders to the BHI Board of Directors," said BioHealth Innovation's President & CEO Richard Bendis. "Dan brings a unique perspective from his role at the helm of one of the leading specialty pharmaceutical companies while Jens will provide important insight as the head of the corporate venture capital arm of GlaxoSmithKline (GSK). I'm also incredibly pleased that GSK, after having acquired Human Genome Sciences (one of the original investors in BHI), will continue to support BHI and has expressed an understanding of the importance of the mission of our organization."

ARPA-H made its final hub location decision, selecting the historic Bowen Building in downtown Washington, D.C. as the site for its Stakeholder & Operations hub.

Why is this important? The new space will allow federal staff and contractors to work in one location, enhancing staff's ability to manage programs and coordinate with federal partners—such as Congress, Health and Human Services, Centers for Medicare and Medicaid Services, U.S. Food and Drug Administration, the National Institutes of Health, and the Administration. Since the agency was authorized in March 2022, much of ARPA-H's D.C. staff has been working remotely or from temporary offices.